Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - Relationship with clinical outcome

Patrizia Ferroni, Mario Roselli, Ilaria Portarena, Vincenzo Formica, Silvia Riondino, Francesca La Farina, Leopoldo Costarelli, Antonia Melino, Gioia Massimiani, Francesco Cavaliere, Raffaele Palmirotta, Fiorella Guadagni

Research output: Contribution to journalArticle

Abstract

Background: Signaling pathways triggered by increased thrombin or plasminogen activator inhibitor-1 (PAI- 1) expression drastically alter the tumor microenvironment, contributing to an adverse outcome. This study aimed to evaluate the prognostic value of coagulation/fibrinolytic activities in breast cancer (BC). Materials and Methods: Coagulation/fibrinolytic activities were investigated in 187 patients with breast cancer, with respect to possible associations with clinicopathological features and survival outcomes. Results: Levels of plasma PAI-1 (p

Original languageEnglish
Pages (from-to)1153-1161
Number of pages9
JournalAnticancer Research
Volume34
Issue number3
Publication statusPublished - Mar 1 2014

Keywords

  • Breast cancer
  • D-dimer
  • Overall survival
  • Plasminogen activator inhibitor-1
  • Relapse-free survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - Relationship with clinical outcome'. Together they form a unique fingerprint.

  • Cite this

    Ferroni, P., Roselli, M., Portarena, I., Formica, V., Riondino, S., La Farina, F., Costarelli, L., Melino, A., Massimiani, G., Cavaliere, F., Palmirotta, R., & Guadagni, F. (2014). Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - Relationship with clinical outcome. Anticancer Research, 34(3), 1153-1161.